Analyst Conference Summaries

Biotechnology Investor Aids

Seagen (Seattle Genetics)
SGEN

conference date: October 29, 2020 @ 1:30 PM Pacific Time

Seattle Genetics New Data Strengthens Buy Proposition [October 8, 2019]

Seattle Genetics Fairly Valued [May 14, 2018]

AML Therapies: Seattle Genetics vs. GlycoMimetics [July 15, 2016 at Seeking Alpha]

Seattle Genetics: The Long View [February 25, 2015 at SeekingAlpha]

2020
Seagen Genetics
Q1 2020
Seattle
Genetics
Q2 2020
Seagen
Q3 2020
 
April 30, 2020 July 30, 2020 Oct. 29, 2020  
2019
Seattle
Genetics
Q1 2019
Seattle
Genetics
Q2 2019
Seattle
Genetics
Q3 2019
Seattle
Genetics
Q4 2019
April 25, 2019 July 16, 2019 Oct. 29, 2019 Feb. 6, 2020
2018
Not Available
Q3 2018
April 26, 2018
July 26, 2018
Oct. 25, 2018
Feb. 7, 2019
2017
April 27, 2017
July 27, 2017
Oct. 26, 2017
Feb. 6, 2018
2016
04/28/2016
07/26/2016
10/27/2016
02/09/2017
2015
04/30/2015
07/30/2015
10/29/2015
02/09/2016
2014
not available
07/31/2014
10/30/2014
02/10/2015

Seattle Genetics develops antibody-based therapies for cancer. Adcetris is its first commercially approved therapy.

Seattle Genetics web site
Seattle Genetics investor relations page


 

Search

More Analyst Conference Pages:

 AGEN
 ALXN
 AMAT
 AMGN
 APRE
 ARWR
 BIIB
 BMY
 DRNA
 GILD
 GLYC
 INCY
 INO
 ISRG
 MCHP
 MRNA
 REGN
 TTPH
 VBLT
 VSTM
 XLNX
 XLRN

 
 

Disclaimer: Our analyst summaries may include both our condensations of statements made by company representatives and our own analysis. They are not covered by any warranty. We cannot guarantee anything said by company representatives is true. We try not to make errors, but it is possible. These are my personal notes, not investment advise.

Copyright 2020 William P. Meyers